Skip to main content

Table 1 Comparison of patient characteristics for overall and breast cancer subtypes

From: Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

Character Overall (number = 79) mrTNBC (number = 18) Luminal/HER2-negative (number = 41) HER2-positive (number = 18) P-valuea
Median age (range) 57 (30 to 77) 55 (30 to 65) 55 (39 to 76) 62 (51 to 70) 0.019
Performance status      0.046
  0/1 58/21 14/4 32/9 11/7  
Median time to the first PPV from recurrence, months (range) 35 (1.2 to 165) 8 (1.2 to 99) 40 (2 to 123) 55 (19 to 165) 0.101
Histopathology      0.079
  Ductal carcinoma 71 16 37 17  
  Lobular carcinoma 4 1 2 1  
  Others 4 1 2   
Positive status of HLA-A24 55 10 29 14 0.039
Positive status of HLA-A2 22 6 8 8 0.015
Visceral metastasis      0.009
  Yes/No 60/19 8/6 29/11 16/2  
Brain metastasis      0.002
  Yes/No 11/68 3/11 2/38 6/12  
Median duration of previous chemotherapies, months (range) 12 (2 to 148) 9 (4 to 43) 12 (2 to 9) 37 (10 to 148) <0.0001
Usage of previous standard chemotherapy      
  Anthracycline 50 16 22 12 0.003
  Taxane 58 16 24 17 0.0006
  Trastuzumab 18   3 15 <0.0001
Regimen number of previous chemotherapies      0.008
  <4/≥4 36/36 8/9 22/14 6/12  
Combined therapies      
  Oral chemotherapy 19 5 8 6 0.060
  Infusion chemotherapy 32 10 15 7 0.038
  Anti-HER2 therapy 11    11 <0.0001
  Hormonal therapy 23 2 17 4 0.006
Median times of peptide vaccination 14 (2 to 39) 12 (2 to 30) 15 (4 to 39) 12 (6 to 22) 0.021
  1. aThe Mann-Whitney U test and Fisher-Freeman-Halton exact test were performed to examine P-values for continuous values and categorical values. HER2, human epidermal growth factor 2; HLA, human leukocyte antigens; mrTNBC, metastatic recurrent triple-negative breast cancer; PPV, personalized peptide vaccination.